Entrada Therapeutics Inc 2024年度报告

FORM 10-K Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☐ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes☐No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report. ¨ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements. ¨ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☐ The aggregate market value of registrant’s common equity held by non-affiliates of registrant on June 30, 2024 was approximately $392.5 millionbased upon the closing sale price of the common stock as reported on The Nasdaq Global Market as of June 28, 2024 (the last business day of theregistrant's most recently completed second fiscal quarter). In determining the market value of non-affiliate common stock, shares of the registrant’scommon stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily aconclusive determination for other purposes. As of February 20, 2025, the registrant had 37,594,630 shares of common stock, $0.0001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE Table of ContentsPortions of the registrant's definitive Proxy Statement for its 2025 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant's fiscal year ended December 31, 2024, areincorporated by reference into Part III of this Annual Report on Form 10-K. Table of Contents TABLE OF CONTENTS Page PART I Item 1.Business9Item 1A.Risk Factors42Item 1B.Unresolved Staff Comments104Item 1C.Cybersecurity104Item 2.Properties105Item 3.Legal Proceedings105Item 4.Mine Safety Disclosures106 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters andIssuer Purchases of Equity Securities Item 6.Reserved108Item 7.Management’s Discussion and Analysis of Financial Condition andResults of Operations108Item 7A.Quantitative and Qualitative Disclosures About Market Risk119Item 8.Financial Statements and Supplementary Data120Item 9.Changes in and Disagreements with Accountants on Accounting andFinancial Disclosure151Item 9A.Controls and Procedures151Item 9B.Other Information151Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections152 PART III Item 10.Directors, Executive Officers and Corporate Governance153Item 11.Executive Compensation153Item 12.Security Ownership of Certain Beneficial Owners and Management andRelated Stockholder Matters153Item 13.Certain Relationships and Related Transactions, and DirectorIndependence153Item 14.Principal Accounting Fees and Services153 PART IV Item 15.Exhibits and Financial Statement Schedules154Item 16.Form 10-